Evidence map›Paper›PMID 40573286›Full record

ReviewPharmaceuticals (Basel, Switzerland)2025

Elise Si Ahmed Charrier, Alexandra Dassonville-Klimpt, Claire Andréjak, Pascal Sonnet

Abstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Complete genome sequence of a multi-drug-resistantMicrobiology resource announcements · 2026
    Article
  3. Review
  4. Treatment strategies forBreathe (Sheffield, England) · 2026
    Article
  5. Co-infection withFrontiers in medicine · 2026
    Review
  6. The N-Terminal Extension of theAntibiotics (Basel, Switzerland) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Elise Si Ahmed CharrierAgents Infectieux, Résistance et Chimiothérapie, AGIR, Université de Picardie-Jules-Verne, UR 4294, UFR de Pharmacie, 1 Rue des Louvels, CEDEX 1, 80037 Amiens, France.ORCID 0000-0003-2231-648X
Alexandra Dassonville-KlimptAgents Infectieux, Résistance et Chimiothérapie, AGIR, Université de Picardie-Jules-Verne, UR 4294, UFR de Pharmacie, 1 Rue des Louvels, CEDEX 1, 80037 Amiens, France.ORCID 0000-0002-2891-9102
Claire AndréjakAgents Infectieux, Résistance et Chimiothérapie, AGIR, Université de Picardie-Jules-Verne, UR 4294, UFR de Pharmacie, 1 Rue des Louvels, CEDEX 1, 80037 Amiens, France.
Pascal SonnetAgents Infectieux, Résistance et Chimiothérapie, AGIR, Université de Picardie-Jules-Verne, UR 4294, UFR de Pharmacie, 1 Rue des Louvels, CEDEX 1, 80037 Amiens, France.ORCID 0000-0003-0118-9151

Funding

Fédération Hospitalo-Universitaire RESPIRE. 2022-2025Université de Picardie Jules Verne 2022-2025
6 · The paper itself

Abstract

Worldwide, several million people are infected with mycobacteria such as

Indexed as

anti-MAC compoundsclinical trialsdrug developmentMycobacterium avium complexnon-tuberculous mycobacteria

Identifiers

PMID40573286
PMCPMC12195860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.